A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity

Molecular Therapy Oncology 2026 Open access

Read full text
Authors: Sabine Heinze, Giovanna L. Stadler, Yonghui Zhang, Christine E. Engeland, Thomas F.E. Barth, Johannes P.W. Heidbuechel, Lüder Hinrich Meyer, Michael D. Mühlebach, Klaus‐Michael Debatin, Carmen Dorneburg, Christian P. Beltinger
DOI: 10.1016/j.omton.2026.201127
Cited by: 0
References: 62

Abstract

neuronal models encompassing PBMCs, nor in immunocompromised CD46 transgenic mice, even under additional immunosuppression. Collectively, these findings support further investigations of MV-Blina as a potential treatment for patients with relapsed or refractory BCP-ALL.

Fields of Study & Subjects

Virus-based gene therapy research CAR-T cell therapy research Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Molecular Therapy Oncology
Volume
34
Issue
1
Pages
201127–201127
Publication date
10 January 2026
Language
EN